UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 82

Sortiert nach

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

Cancer treatment reviews, 2014-04, Vol.40 (3), p.445-456

2014

Link zum Volltext

Verfügbarkeit prüfen

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature

PloS one, 2013-01, Vol.8 (1), p.e54193

2013

Link zum Volltext

Verfügbarkeit prüfen

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3342-3350

2013

Link zum Volltext

Verfügbarkeit prüfen

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung

Journal of clinical oncology, 2017-02, Vol.35 (4), p.412-420

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3327-3334

2013

Link zum Volltext

Verfügbarkeit prüfen

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.211-218

2014

Link zum Volltext

Verfügbarkeit prüfen

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Frontiers in oncology, 2018-08, Vol.8, p.311-311

2018

Link zum Volltext

Verfügbarkeit prüfen

Lung cancer stem cells: The root of resistance

Cancer letters, 2016-03, Vol.372 (2), p.147-156

2016

Link zum Volltext

Verfügbarkeit prüfen

Macrophage and Mast-Cell Invasion of Tumor Cell Islets Confers a Marked Survival Advantage in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-12, Vol.23 (35), p.8959-8967

2005

Link zum Volltext

Verfügbarkeit prüfen

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Frontiers in oncology, 2018-03, Vol.8, p.92-92

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Journal of clinical oncology, 2005-07, Vol.23 (19), p.4265-4274

2005

Link zum Volltext

Verfügbarkeit prüfen

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines

Scientific reports, 2018-01, Vol.8 (1), p.1652-12, Article 1652

2018

Link zum Volltext

Verfügbarkeit prüfen

Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer

Molecular cancer, 2011-03, Vol.10 (1), p.25-25, Article 25

2011

Link zum Volltext

Verfügbarkeit prüfen

Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer

PloS one, 2011-01, Vol.6 (1), p.e14593-e14593

2011

Link zum Volltext

Verfügbarkeit prüfen

IL - 20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF

European journal of cancer (1990), 2011-08, Vol.47 (12), p.1908-1918

2011

Link zum Volltext

Verfügbarkeit prüfen

Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM)

PloS one, 2013-08, Vol.8 (8), p.e70940-e70940

2013

Link zum Volltext

Verfügbarkeit prüfen

KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma

International journal of oncology, 2016-03, Vol.48 (3), p.1290-1296

2016

Link zum Volltext

Verfügbarkeit prüfen

Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin

Translational oncology, 2021-04, Vol.14 (4), p.101025-101025, Article 101025

2021

Link zum Volltext

Verfügbarkeit prüfen

Advances in the systemic therapy of malignant pleural mesothelioma

Nature clinical practice. Oncology, 2008-03, Vol.5 (3), p.136-147

2008

Link zum Volltext

Verfügbarkeit prüfen

Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature

PloS one, 2020-05, Vol.15 (5), p.e0233739-e0233739

2020

Link zum Volltext

Verfügbarkeit prüfen

Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2003-02, Vol.21 (3), p.473-482

2003

Link zum Volltext

Verfügbarkeit prüfen

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC

Cancer biology & therapy, 2014-10, Vol.15 (10), p.1367-1377

2014

Link zum Volltext

Verfügbarkeit prüfen

Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer

Frontiers in oncology, 2021-03, Vol.11, p.615967-615967

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 82

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(81)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(56)
Life Sciences & Biomedicine
(49)
Humans
(43)
Oncology
(42)
Lung Cancer
(22)
Tumors
(22)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Cancer
(17)
Chemotherapy
(17)
Lung Neoplasms - Pathology
(17)
Lung Neoplasms - Drug Therapy
(16)
Adult
(15)
Female
(15)
Male
(15)
Middle Aged
(15)
Lung Neoplasms - Genetics
(14)
Aged
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Cell Line, Tumor
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Lung cancer stem cells: The root of resistance

Macrophage and Mast-Cell Invasion of Tumor Cell Islets Confers a Marked Survival Advantage in Non–Small-Cell Lung Cancer

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines

Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer

Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer

Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer

IL - 20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF

Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM)

KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma

Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin

Advances in the systemic therapy of malignant pleural mesothelioma

Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature

Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non–Small-Cell Lung Cancer

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC

Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer

Aktive Filter

Suchergebnisse filtern